A Phase I Trial of SAR-441169 for the Treatment of Psoriasis
Latest Information Update: 27 Mar 2019
At a glance
- Drugs SAR 441169 (Primary)
- Indications Psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Sanofi
Most Recent Events
- 27 Mar 2019 New trial record
- 21 Mar 2019 According to a Lead Pharma media release, first patient has been dosed in this trial by Sanofi.